Trial Profile

A Phase 2a Randomized, Double-Blind, Placebo-Controlled, Multicenter Dose-Ranging Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 05 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Feb 2026 According to a Tiziana Life Sciences media release, company expects top-line data expected in the first half of 2026.
16 Jan 2026 According to a Tiziana Life Sciences media release, company announced Registered Direct Offering of up to approximately $17.6 Million.The proceeds from this offering enable the company to complete its Phase 2 na-SPMS trial and top line data readouts.
24 Sep 2025 According to a Tiziana Life Sciences media release, study design from this trial will be presented at the 41st Congress of the European Committee for Treatment and Research of Multiple Sclerosis (ECTRIMS), being held September 24-26, 2025, in Barcelona, Spain.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com